001     169692
005     20240229133652.0
024 7 _ |a 10.1007/s00103-021-03368-z
|2 doi
024 7 _ |a pmid:34212206
|2 pmid
024 7 _ |a 1436-9990
|2 ISSN
024 7 _ |a 1437-1588
|2 ISSN
037 _ _ |a DKFZ-2021-01499
041 _ _ |a German
082 _ _ |a 610
100 1 _ |a Jansen, Lina
|0 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
|b 0
|e First author
245 _ _ |a Oral and pharyngeal cancer: incidence, mortality, and survival in Germany[Mundhöhlen- und Pharynxkarzinome: Inzidenz, Mortalität und Überleben in Deutschland].
260 _ _ |a Heidelberg
|c 2021
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1685450892_28113
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:M110#LA:M110#LA:C071# / 2021 Aug;64(8):941-950
520 _ _ |a Lip, oral cavity, and pharynx cancers (ICD-10: C00-C14) describe a heterogeneous group of tumors with strong variations in incidence, mortality, and survival by entity.This work provides a detailed overview of epidemiologic measures for these tumor entities, taking into account heterogeneity in age, sex, location, and stage.Incidence and mortality data for Germany for the years 1999-2016 were extracted from the interactive database of the Center for Cancer Registry Data (ZfKD). Age and stage distributions and five-year relative survival were calculated on the pooled ZfKD data set (diagnosis years 1999-2017).In 2016, overall incidence and mortality for all entities were 17.6 and 7.0 per 100,000 men and 6.5 and 1.8 per 100,000 women, respectively. The five-year relative survival in 2015-2017 was 53 and 63%, respectively. There were marked differences in survival as well as age and stage distributions between entities. Trend analyses showed an increase in age at diagnosis, particularly in male patients, and no change in stage distributions. However, five-year relative survival increased from 45% (men) and 59% (women) in 1999-2002 to 52% and 63% in 2013-2017.The marked heterogeneity of the studied tumors highlights the need to differentiate the analysis by sex and entity for meaningful interpretation of epidemiologic metrics. With the expansion of clinical cancer registration in Germany, additional analyses including other important clinical factors will be possible in the future.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Epidemiology
|2 Other
650 _ 7 |a Mouth neoplasms
|2 Other
650 _ 7 |a Pharyngeal neoplasms
|2 Other
650 _ 7 |a Prognosis
|2 Other
650 _ 7 |a Stage
|2 Other
700 1 _ |a Moratin, Julius
|b 1
700 1 _ |a Waldmann, Annika
|b 2
700 1 _ |a Zaoui, Karim
|b 3
700 1 _ |a Holleczek, Bernd
|b 4
700 1 _ |a Nennecke, Alice
|b 5
700 1 _ |a Pritzkuleit, Ron
|b 6
700 1 _ |a Plinkert, Peter K
|b 7
700 1 _ |a Hoffmann, Jürgen
|b 8
700 1 _ |a Arndt, Volker
|0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
|b 9
|e Last author
773 _ _ |a 10.1007/s00103-021-03368-z
|0 PERI:(DE-600)1470303-8
|n 8
|p 941-950
|t Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|v 64
|y 2021
|x 1437-1588
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169692
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-30
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-30
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BUNDESGESUNDHEITSBLA : 2019
|d 2021-01-30
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-01-30
920 1 _ |0 I:(DE-He78)M110-20160331
|k M110
|l M110 Epidemiologisches Krebsregister Baden-Württemberg
|x 0
920 1 _ |0 I:(DE-He78)C071-20160331
|k C071
|l C071 Cancer Survivorship
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)M110-20160331
980 _ _ |a I:(DE-He78)C071-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21